KR20040082417A - 체중 감량을 위한 수단으로서의 ｃｐｔ-1의 자극 - Google Patents

체중 감량을 위한 수단으로서의 ｃｐｔ-1의 자극 Download PDF

Info

Publication number
KR20040082417A
KR20040082417A KR10-2004-7012208A KR20047012208A KR20040082417A KR 20040082417 A KR20040082417 A KR 20040082417A KR 20047012208 A KR20047012208 A KR 20047012208A KR 20040082417 A KR20040082417 A KR 20040082417A
Authority
KR
South Korea
Prior art keywords
cpt
activity
fatty acid
malonyl
coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7012208A
Other languages
English (en)
Korean (ko)
Inventor
튜페리제이건엔
랜드리레슬리이
로넷가브리엘
쿠하즈다프랜시스피
Original Assignee
존스 홉킨스 유니버시티 스쿨 오브 메디슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 존스 홉킨스 유니버시티 스쿨 오브 메디슨 filed Critical 존스 홉킨스 유니버시티 스쿨 오브 메디슨
Publication of KR20040082417A publication Critical patent/KR20040082417A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pediatric Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR10-2004-7012208A 2002-02-08 2003-02-10 체중 감량을 위한 수단으로서의 ｃｐｔ-1의 자극 Ceased KR20040082417A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35448002P 2002-02-08 2002-02-08
US60/354,480 2002-02-08
PCT/US2003/003839 WO2003066043A1 (en) 2002-02-08 2003-02-10 Stimulation of cpt-1 as a means to reduce weight

Publications (1)

Publication Number Publication Date
KR20040082417A true KR20040082417A (ko) 2004-09-24

Family

ID=27734382

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7012208A Ceased KR20040082417A (ko) 2002-02-08 2003-02-10 체중 감량을 위한 수단으로서의 ｃｐｔ-1의 자극

Country Status (12)

Country Link
US (4) US20050143467A1 (https=)
EP (1) EP1471906A4 (https=)
JP (2) JP2005523270A (https=)
KR (1) KR20040082417A (https=)
CN (1) CN1313089C (https=)
AU (2) AU2003215111A1 (https=)
BR (1) BR0307421A (https=)
CA (1) CA2474884A1 (https=)
EA (1) EA007029B1 (https=)
IL (1) IL163312A (https=)
MX (1) MXPA04007556A (https=)
WO (1) WO2003066043A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471906A4 (en) * 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
EP2386551A1 (en) * 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20080119548A1 (en) * 2004-03-18 2008-05-22 Ronnett Gabrielle V Control Of Feeding Behavior By Changing Neuronal Energy Balance
CN101022792A (zh) * 2004-05-26 2007-08-22 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
BRPI0610877A2 (pt) * 2005-06-06 2010-08-03 Hoffmann La Roche compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos
WO2007014248A2 (en) * 2005-07-26 2007-02-01 Johns Hopkins University Method of reducing food intake
ATE418603T1 (de) * 2005-08-29 2009-01-15 Hoffmann La Roche Kristallstrukturen von carnitine palmitoyltransferase-2 (cpt-2) und deren verwendung
ES2405259B1 (es) * 2011-11-25 2014-09-29 Centro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn) Uso del enantiómero (+)-c75 para el tratamiento de la obesidad.
WO2013155528A2 (en) * 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574639A (en) 1897-01-05 Gold-saving device
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
AU5802499A (en) * 1998-09-01 2000-03-21 Amway Corporation Diet composition and method of weight management
AU784495B2 (en) * 1999-11-12 2006-04-13 Johns Hopkins University School Of Medicine, The Treating cancer by increasing intracellular malonyl coa levels
KR20030016228A (ko) * 2000-02-16 2003-02-26 존스 홉킨스 유니버시티 스쿨 오브 메디슨 신경펩티드 ｙ 농도의 감소에 의해 유도되는 체중 감량
WO2002079501A1 (en) * 2001-03-30 2002-10-10 Trustees Of Boston University Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
EP1471906A4 (en) * 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
US20040161803A1 (en) * 2002-04-01 2004-08-19 Corkey Barbara E. Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
EP1534263A4 (en) 2002-07-01 2006-10-11 Fasgen Llc NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF ADMINISTRATION THEREFOR
EP2386551A1 (en) 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Also Published As

Publication number Publication date
CA2474884A1 (en) 2003-08-14
AU2003215111A1 (en) 2003-09-02
US20050143467A1 (en) 2005-06-30
CN1638758A (zh) 2005-07-13
WO2003066043A1 (en) 2003-08-14
BR0307421A (pt) 2004-12-28
IL163312A (en) 2011-12-29
US7459481B2 (en) 2008-12-02
EP1471906A1 (en) 2004-11-03
JP2010047594A (ja) 2010-03-04
US20090124684A1 (en) 2009-05-14
AU2008249144A1 (en) 2008-12-11
MXPA04007556A (es) 2005-12-05
CN1313089C (zh) 2007-05-02
JP2005523270A (ja) 2005-08-04
EP1471906A4 (en) 2006-02-01
US20070087037A1 (en) 2007-04-19
US20050106217A1 (en) 2005-05-19
EA200401052A1 (ru) 2005-02-24
EA007029B1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
US20090124684A1 (en) Stimulation Of CPT-1 As A Means To Reduce Weight
Lee et al. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth
Blankson et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans
Koide et al. Cyclic AMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. Synergism with the induction elicited by inflammatory cytokines.
Chen et al. AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation
Hornberger et al. Mechanical stimuli regulate rapamycin-sensitive signalling by a phosphoinositide 3-kinase-, protein kinase B-and growth factor-independent mechanism
Masamune et al. Ligands of peroxisome proliferator-activated receptor-γ block activation of pancreatic stellate cells
Eskew et al. Cellular protection mechanisms against extracellular heme: heme-hemopexin, but not free heme, activates the N-terminal c-Jun kinase
Yoshida et al. Negligible direct lactate oxidation in subsarcolemmal and intermyofibrillar mitochondria obtained from red and white rat skeletal muscle
Petridou et al. Long-term exercise increases the DNA binding activity of peroxisome proliferator–activated receptor γ in rat adipose tissue
Pereira et al. Effect of insulin and contraction up on glucose transport in skeletal muscle
Rådegran et al. Adenosine and nitric oxide in exercise‐induced human skeletal muscle vasodilatation
MacRitchie et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension
Cronin et al. Tumor promoters enhance basal and growth hormone releasing factor stimulated cyclic AMP levels in anterior pituitary cells
WO2008016730A2 (en) Compositions and methods for reducing cellular fat
JP5539653B2 (ja) 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法
Cruz et al. LPS induction of IκB-α degradation and iNOS expression in a skin dendritic cell line is prevented by the Janus kinase 2 inhibitor, tyrphostin B42
Gu et al. Berberine ameliorates nonalcoholic fatty liver disease-induced bone loss by inhibiting ferroptosis
Hall et al. Assessing the physiological concentration and targets of nitric oxide in brain tissue
Kawanaka et al. Effects of high-intensity intermittent swimming on glucose transport in rat epitrochlearis muscle
Zhang et al. Inhibition of skeletal muscle atrophy during torpor in ground squirrels occurs through downregulation of MyoG and inactivation of Foxo4
Srivastava et al. Synergistic effects of 8-chlorocyclic-AMP and retinoic acid on induction of apoptosis in Ewing's sarcoma CHP-100 cells.
Gong et al. Exogenous nitric oxide reduces oxygen consumption of isolated ventricular myocytes less than other forms of guanylate cyclase stimulation
KR20120094308A (ko) 2,4-비스(ｐ-하이드록시페닐)-2-부텐알을 유효성분으로 함유하는 염증 질환 또는 관절염 치료 및 예방용 약학조성물
Walaszek et al. Repression by sustained‐release β‐glucuronidase inhibitors of chemical carcinogen‐mediated induction of a marker oncofetal protein in rodents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040806

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080211

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091102

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20100823

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110816

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100823

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20091102

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I